


CLAIMS

- 5 1. Method for the conditioning of an extracorporeal device for the extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease, wherein a solution containing a reagent having the general formula:



wherein the biotin moieties are natural biotin or derivatives thereof,

- 30 wherein a, b, and c are linkers, which are same or different, and wherein d is a trifunctional crosslinking moiety,

is passed through a device having biotin binding ability, wherein the reagent is bound to the device, and
 35 wherein said device thereby is converted from a biotin binding to a toxic material binding device.

2. Method according to claim 1, wherein the trifunctional cross-linking moiety, containing three functional groups that are nucleophilic or are reactive with
 40 nucleophiles, is an aliphatic or aromatic compound, preferably an aromatic compound with 1,3,5-substitution, most preferably derivatives of 1,3,5-benzene tricarboxy-

RECEIVED

12/29 9/30?

Sub
A

lic acid, 3,5-diaminobenzoic acid, or 5-amino-1,3-dicarboxybenzene.

3. Method according to claim 1, wherein the toxin binding moiety is a molecule that binds with high affinity to a toxic material with or without an effector molecule and is chosen from the group comprising monoclonal antibodies including fragments or engineered counterparts thereof, aptamers, peptides, oligodeoxynucleosides including binding fragments thereof, intercalation reagents including dyes, chemotherapy agents, natural substances and metal chelates that specifically bind with toxic material with or without an effector molecule or to an effector molecule attached to the toxic material.

4. Method according to claim 1, wherein one or more of the linkers a, b, and c is/are linear or branched and contain(s) water solubilizing functionalities or side groups containing amines, carboxylates or hydroxyl functionalities, preferably an alpha carboxylate or an N-methyl group in a view to improving the stability towards enzymatic cleavage of the biotinamide bond between the biotin moiety or a derivative thereof and the spacer.

5. Method according to claim 1, wherein the biotin derivatives are chosen from the group comprising nor-biotin, homobiotin, oxybiotin, iminobiotin, desthiobiotin, diaminobiotin, biotin sulfoxide, biotin sulfone or other biotin molecules having the ability to bind to avidin, streptavidin and derivatives thereof.

6. Method according to claim 4, wherein the linkers a and b provide a minimum of 20 Å and a maximum of 60 Å between the trifunctional cross-linking moiety and each biotin moiety carboxylate carbon atom when measured in a fully linearized form.

Sub
A
con.

SECRET

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	


5 radionuclides bound to other compounds, ingested toxins, toxins produced by bacteria, preferably endotoxins or enterotoxins, toxins produced by viral infections, toxins produced by disease states, diseased cells, cells involved in the immune response, anti-blood group anti-
10 bodies, anti-HLA antibodies, anti-xenoantibodies or any other undesirable endogenous component present in bodily fluid at an undesirable level as a result of a disease, disorder or incompatibility with therapeutic treatment, preferably TNF and cytokinins, or any exogenous component
15 that is or could be involved in a disease, disorder or medical incompatibility, preferably biotin binding molecules.

8. Method according to claim 7, wherein the biotin binding molecule is chosen from the group comprising avidin, streptavidin or derivatives or fragments thereof having essentially the same binding function to biotin as avidin or streptavidin, and is optionally bound to an effector molecule.

9. Method according to claim 3, wherein the effector molecule is a radionuclide, a cytotoxic agent, a chelating agent for binding of radionuclides, a chemotherapy agent, a natural toxin or a derivative thereof, or a synthetic toxin.

10. Method according to any of the previous
30 claims, wherein the toxin binding moiety is biotin, the
spacers a, b, and c are 4, 7, 10-trioxa-1,13-tridecane-
diamine and the trifunctional cross-linking moiety is 5-
amino-1,3-dicarboxybenzene.



Sub
A'
cont.




Station	Time	Lat.	Long.	Alt.	Temp.	Wind	Clouds	Remarks
1	0800	34° 15' N	122° 00' W	10	55.0	0	0	Clear
2	0900	34° 30' N	121° 45' W	10	55.5	0	0	Clear
3	1000	34° 45' N	121° 30' W	10	56.0	0	0	Clear
4	1100	35° 00' N	121° 15' W	10	56.5	0	0	Clear
5	1200	35° 15' N	121° 00' W	10	57.0	0	0	Clear
6	1300	35° 30' N	120° 45' W	10	57.5	0	0	Clear
7	1400	35° 45' N	120° 30' W	10	58.0	0	0	Clear
8	1500	36° 00' N	120° 15' W	10	58.5	0	0	Clear
9	1600	36° 15' N	120° 00' W	10	59.0	0	0	Clear
10	1700	36° 30' N	119° 45' W	10	59.5	0	0	Clear
11	1800	36° 45' N	119° 30' W	10	60.0	0	0	Clear
12	1900	37° 00' N	119° 15' W	10	60.5	0	0	Clear
13	2000	37° 15' N	119° 00' W	10	61.0	0	0	Clear
14	2100	37° 30' N	118° 45' W	10	61.5	0	0	Clear
15	2200	37° 45' N	118° 30' W	10	62.0	0	0	Clear
16	2300	38° 00' N	118° 15' W	10	62.5	0	0	Clear
17	0000	38° 15' N	118° 00' W	10	63.0	0	0	Clear
18	0100	38° 30' N	117° 45' W	10	63.5	0	0	Clear
19	0200	38° 45' N	117° 30' W	10	64.0	0	0	Clear
20	0300	39° 00' N	117° 15' W	10	64.5	0	0	Clear
21	0400	39° 15' N	117° 00' W	10	65.0	0	0	Clear
22	0500	39° 30' N	116° 45' W	10	65.5	0	0	Clear
23	0600	39° 45' N	116° 30' W	10	66.0	0	0	Clear
24	0700	40° 00' N	116° 15' W	10	66.5	0	0	Clear

Sub
A'
cont.


11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100




☐ a) $X = \text{NH} - \text{COO}$
☐ b) $X = \text{NH}_2$




7




1




☐ 天 X=1000
☐ 10 X=H




2




9




12



5



1



12. Method for the extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease, wherein the toxic material, optionally including an effector molecule, which has been added to the blood circulation of a mammal and kept therein for a certain time in order to be concentrated to target tissue or cells but which have not been concentrated to said target tissue or cells, directly or through other previously administered molecules, is completely or partially cleared from the blood circulation by passing the mammalian blood or plasma through an extracorporeal device containing a reagent as defined in any one of claims 1-11.

13. Method according to claim 12, wherein the toxin binding moiety of the reagent is biotin or a derivative thereof, wherein

a) biotinylated targeting biomolecules added to the blood circulation of the mammal but not concentrated to the target tissue or cells are cleared from the blood circulation by passage through an extracorporeal biotin-binding device, and

b) biotin-binding molecules, administered to the blood circulation after step a), each conjugated to an effector molecule, but not concentrated to the target tissue or cells, are cleared from the blood circulation

by passage through an extracorporeal device containing said reagent for specific adsorption of the biotin-binding molecules and the effector molecules conjugated thereto.

5 14. Method according to claim 13, wherein

 a) the biotinylated targeting biomolecules each are conjugated with an effector molecule, and which have been administered to the blood circulation in order to monitor the tumor uptake by detection of the effector molecule by
10 a gamma-camera, PET-scan, MRI or other in vivo diagnostic techniques, and wherein the effector molecule in step b) is a cell killing radionuclide or a cytotoxic agent.

 15. Method according to claim 13, wherein in step b) the biotin-binding molecules are not conjugated to
15 effector molecules, and in a further step c) a conjugate between an effector molecule and biotin or the reagent is added to the blood circulation of the mammal, and, optionally, the blood is cleared from said conjugate not concentrated to the target or tissue cells by passage
20 through an extracorporeal biotin-binding device.

 16. Method according to claim 12, wherein the toxin binding moiety of the reagent is biotin or a derivative thereof, wherein

 a) biotin-binding molecules attached to targeting
25 molecules added to the blood circulation of the mammal but not concentrated to the target tissue or cells are cleared from the blood circulation by passage through an extracorporeal device containing said reagent for specific adsorption of the biotin-binding molecules, and,
30 optionally,

 b) biotinylated molecules, either with biotin or with the reagent, administered to the blood circulation after step a), each conjugated to an effector molecule,

but not concentrated to the target tissue or cells, are cleared from the blood circulation by passage through an extracorporeal biotin-binding device.

17. Method according to any of claims 13-16, wherein
5 the biotinylated targeting biomolecules are targeting molecules containing natural biotin or derivatives thereof,

the biotin-binding molecules are molecules containing avidin, streptavidin or derivatives thereof,

10 the biotinylated molecules are radiolabelled biotin derivatives containing a radiometal chelation moiety, and the effector molecule is a radionuclide or a cytotoxic agent.

18. Method according to claim 12 for the simultaneous blood clearance of multiple anti-HLA antibodies,
15 multiple anti-blood group antibodies or multiple anti-xenoantibodies, preferably prior to organ or cell transplantation, wherein it comprises an extracorporeal device containing said reagent or several reagents having
20 different specific toxin binding moieties.

19. Extracorporeal device for the extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease, wherein it comprises a biotin binding molecule
25 bound to a reagent as specified in any one of claims 1-11.

20. Extracorporeal device according to claim 19, wherein the device is a column, the biotin binding molecule is avidin or streptavidin and the reagent is a
30 tribiotinylated reagent.

add
A2 7